Annoviant

Annoviant recently announced it was awarded a $2.99 million National Institutes of Health grant to advance its TxGuard pulmonary-valved conduit for pediatric heart disease.

The grant, an SBIR Phase 2 b grant, will help the Atlanta-based company accelerate the development and commercialization of its technology. It builds upon the company’s previous Phase 2 NIH grant issued in 2021.

“We are delighted to receive this additional grant from the NIH, accompanied by matching funds from our esteemed investors. This marks a significant milestone for Annoviant as we accelerate our pursuit of impactful innovation to save lives,” Co-founder and CEO Ajay Houde said in a news release.

Annoviant’s TxGuard is used in conduit replacements to treat congenital heart disease (CHD). According to the company, the condition affects approximately 40,000 newborns annually in the U.S. and 1.35 million worldwide.

The device is resistant to calcifica…

[Image from Annoviant’s website]Annoviant announced today that it received a $1.85 million NIH grant to help further the development and commercialization of its TxGuard.

Atlanta-based Annoviant’s latest grant for the TxGuard pulmonary-valved conduit represents a continuation of the Phase I Small Business Technology Transfer (STTR) grant the company received in 2019, according to a news release.

Get the full story at our sister site, Medical Design & Outsourcing.